← All stories
Earnings
Hikma Pharmaceuticals (LSE:HIK): Why Did A Buyback Fail To Sweeten The Guidance?
Highlights Group revenue and operating profit guidance was reaffirmed for the full year Injectables growth expectations were framed more cautiously than the market anticipated The company confirmed it is stepping away from a small compoundi…
Covered by 1 outlet
All coverage · 1 article